AnPac Bio-Medical Science (NASDAQ:ANPC) surges 28% premarket on the heels of positive results from a successfully completed multi-year lung cancer prognosis and recurrence study in collaboration with a major hospital in China.
The study began in 2014 with the enrollment and completed all follow-up and testing in 2020. Approx. 1,000 confirmed lung cancer patients were tested using AnPac Bio’s cancer differentiation analysis (CDA) technology.
Initial results indicate that CDA technology could act as a viable tool for measuring and evaluating lung cancer treatment, efficacy and recurrence following remission.
A summary of the results from the study are as follows:
CDA values are statistically different between complete response (CR) patient group and stable disease patient group, and between CR group and progressive disease group, indicating that CDA could be used for cancer prognosis.
Patient groups with higher CDA values (higher cancer risk or progression) have statistically lower five-year survival probability than patient groups with lower values which shows that CDA values could be a good indicator predicting the outcome of a treatment (survival probability).
In a number of cases, CDA values increased ahead of the onset of the cancer’s recurrence, indicating that the technology could potentially be used as a recurrence monitor.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.